$14.28, $35.71, $4,000,000 or $10,000,000/share all sounds good to me someday down the road.  For now I think I'll just go with the company's own current enterprise value estimate (from Jan 9/17 BioTech Showcase) of $250 million which on a fully diluted basis is roughly $1.85/share.  I would agree that this number could change dramatically and quickly if and when we have some great efficacy data but for valuation right now, comparing some good ph 1 PK data to marketed drugs generating billions of dollars is a bit outlandish.  JMO